| Identification | Back Directory | [Name]
2-[3,5-bis(trifluoromethyl)phenyl]-3,3,3-trideuterio-N-methyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-(trideuteriomethyl)propanamide | [CAS]
2070015-31-3 | [Synonyms]
2-[3,5-bis(trifluoromethyl)phenyl]-3,3,3-trideuterio-N-methyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-(trideuteriomethyl)propanamide
Netupitant D6Q: What is
Netupitant D6 Q: What is the CAS Number of
Netupitant D6 Q: What is the storage condition of
Netupitant D6 Q: What are the applications of
Netupitant D6 | [Molecular Formula]
C30H32F6N4O | [MDL Number]
MFCD28900722 | [MOL File]
2070015-31-3.mol | [Molecular Weight]
578.6 |
| Hazard Information | Back Directory | [Description]
Netupitant-d6 is intended for use as an internal standard for the quantification of netupitant by GC- or LC-MS. Netupitant is an insurmountable antagonist of the neurokinin-1 (NK1) receptor (Ki = 0.95 nM in CHO cells expressing the human recombinant receptor).1 It is selective for human NK1 over human NK2 and NK3 and rat NK1 (Kis = >1,500 nM) and over 50 G protein-coupled receptors, monoamine transporters, and ion channels when used in the nanomolar range.2 Netupitant decreases the maximal response to substance P-induced contractions in isolated guinea pig ileum with long-lasting effects. It also dose-dependently inhibits the substance P-induced scratching, biting, and licking response in mice when used at doses ranging from 1 to 10 mg/kg and decreases NK agonist-induced foot tapping in gerbils (ID50s = 1.5 mg/kg, i.p., or 0.5 mg/kg, oral). | [Uses]
Netupitant-d6 is the deuterium labeled Netupitant (CID-6451149), which is a highly potent and selective, orally active neurokinin-1 (NK1) receptor antagonist[1]. | [storage]
Store at -20°C | [References]
1. Hoffmann, T., B?s, M., Stadler, H., et al. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists Bioorg. Med. Chem. Lett. 16(5),1362-1365(2006).
2. Rizzi, A., Campi, B., Camarda, V., et al. In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant Peptides 37(1),86-97(2012). |
|
|